CannPal Advances Research Through Agreement with The University of Queensland

Key Highlights

  • CannPal has entered into a research services agreement with The University of Queensland
  • The University of Queenlands’s TetraQ Research Infrastructure Centre will provide bio-analytical services for CannPal’s pharmacokinetic and safety studies
  • TetraQ will develop and validate a method for quantification of cannabidiol and tetrahydrocannabinol concentration in dog plasma samples
  • Over 48 dogs will be evaluated over the course of three phases, with results from phases 1 and 2 anticipated in Q2 2018
  • The resulting bioanalytical services will be subject to full validation in accordance with regulatory guidelines

Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce it has entered into a research services agreement with The University of Queensland.

The University of Queensland’s TetraQ Research Infrastructure Centre (“TetraQ”) assists research groups within the university and selected external research groups with bioanalytical services.

The research services agreement outlines the terms in which TetraQ will develop and validate a bioanalytical method for simultaneous quantitation of cannabidiol (CBD)and tetrahydrocannabinol (THC) concentrations in dog plasma. TetraQ will subsequently analyze over 850 dog plasma samples in three study phases for CBD and THC concentrations, as part of CannPal’s pharmacokinetic and safety studies scheduled for Q1 2018.

The bioanalytical studies will be conducted in accordance with OECD Good Laboratory Practice (GLP) and also related United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) bioanalytical method guidances.

CannPal is completing the studies as part of its development plan for CPAT-01, a regulatory approved pain treatment for dogs. The market for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), the most commonly used treatments for pain in companion animals, is worth more than $1.4b globally, but NSAIDs come with a long list of side effects.

The Company believes that significant value can be created for shareholders by providing veterinarians with a standardized and dosage-controlled medicine using whole plant cannabis extracts, without the side effects associated with current treatments.

CannPal has planned a comprehensive pharmacokinetic and safety study to take place in Q1 2018. The Company is working with leading veterinary research organizations Klifovet, and Invetus Limited, to design and run clinical studies in Australia with TetraQ now contracted to analyse and report on plasma CBD and THC results.

October 31, 2017 Latest News, News , ,
About Admin

Leave a Reply

Your email address will not be published. Required fields are marked *